Secondary Prevention by Structured Semi-Interactive Stroke Prevention Package in India (SPRINT INDIA) study protocol

Rationale Recurrent stroke, cardiovascular morbidity, and mortality are important causes of poor outcome in patients with index stroke. Despite the availability of best medical management recurrent stroke occur in up to 15–20% of patients with stroke in India. Education for stroke prevention could b...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Stroke 2020-01, Vol.15 (1), p.109-115
Main Authors: Kate, Mahesh Pundlik, Arora, Deepti, Verma, Shweta Jain, Sylaja, PN, Renjith, Vishnu, Sharma, Meenakshi, Pandian, Jeyaraj Durai
Format: Article
Language:English
Subjects:
Acute Coronary Syndrome - prevention & control
Adolescent
Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Patient Education as Topic - methods
Randomized Controlled Trials as Topic
Secondary Prevention - methods
Stroke - mortality
Stroke - prevention & control
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale Recurrent stroke, cardiovascular morbidity, and mortality are important causes of poor outcome in patients with index stroke. Despite the availability of best medical management recurrent stroke occur in up to 15–20% of patients with stroke in India. Education for stroke prevention could be a strategy to prevent recurrent strokes. Hypothesis We hypothesize that a structured semi-interactive stroke prevention package can reduce the risk of recurrent strokes, acute coronary artery syndrome, and death in patients with sub-acute stroke at the end of one year. Design Secondary Prevention by Structured Semi-Interactive Stroke Prevention Package in INDIA (SPRINT INDIA) is a multi-center stroke trial involving 25 centers under the Indian Stroke Clinical Trial Network. Patients with first ever sub-acute stroke within two days to three months of onset, age 18–85 years, mRS
ISSN:1747-4930
1747-4949
DOI:10.1177/1747493019895653